NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Thursday that its third quarter revenues fell 2 percent mostly due to a 5 percent dip in revenues from its non-invasive heart transplant rejection test AlloMap.

For the three months ended Sept. 30, the firm reported total revenues of $12.2 million, down from $12.5 million in Q3 2016, but beating the average Wall Street estimate for revenues of $12.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.